amgen maritide - Search News

Amgen Inc. Q4 Profit Decreases

Amgen profit beats estimates, next MariTide studies start by mid-year

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed a hold on an early-stage trial of a different experimental weight-loss drug.

Business Insider · 9h

Amgen Inc. Q4 Profit Decreases, But Beats Estimates

Amgen Inc. (AMGN) reported a profit for fourth quarter that decreased from the same period last year but beat the Street estimates.

The Motley Fool · 8h

Amgen Surpasses Q4 Earnings Forecasts

Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

Amgen, obesity and FDA

STAT · 7h

Study of Amgen’s early obesity candidate paused by FDA

The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to reopen the study.

Business Insider · 9h

Amgen says Phase 1 AMG 513 obesity study placed on clinical hold by FDA

Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with

YAHOO!Finance · 8h

Amgen Discloses FDA Paused Study of Early-Stage Obesity Drug

Amgen Inc.’s disclosed that US regulators paused the study of an early-stage obesity drug, a lucrative market the company is trying to crack.Most Read from BloombergState Farm Seeks Emergency Californ

The Motley Fool: An inside look at Amgen’s fall

Shares of the company began plunging in November, but its overall strength should set the stock up for some serious potential ...

The Motley Fool: Not-so-bad cinical trial results

Shares of Amgen (Nasdaq: AMGN) started crashing in early November and didn’t improve when the company released data from a ...

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

pharmaphorum5d

Amgen's big reveal of obesity data falls a little flat

Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...

STAT7d

The Trump administration’s latest decisions on federal health agencies, summarized and explained

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

ENDPOINTS NEWS4h

Amgen announces hold on Ph1 obesity candidate, pipeline cuts

Amgen's obesity drug AMG-513 on clinical hold; company reaffirms obesity market ambitions while advancing MariTide program ...

1don MSN

Amgen's SWOT analysis: stock outlook amid obesity drug race

Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...

Amgen Q4 Earnings Preview: Street expects revenue to rise more than 8%

Biopharmaceutical company Amgen (AMGN) is set to announce its fourth quarter earnings results on Tuesday, February 4th, after ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results